Asian Stocks Estimated Below Intrinsic Value In June 2025
Amidst escalating geopolitical tensions in the Middle East and ongoing trade discussions, Asian markets have been navigating a complex landscape, with mixed performances across major indices. As investors seek opportunities in this environment, identifying stocks that are potentially undervalued relative to their intrinsic value can be a strategic approach to capitalizing on market fluctuations.
Name
Current Price
Fair Value (Est)
Discount (Est)
Taiwan Union Technology (TPEX:6274)
NT$216.50
NT$424.21
49%
StemCell Institute (TSE:7096)
¥1070.00
¥2118.09
49.5%
Shenzhen KSTAR Science and Technology (SZSE:002518)
CN¥21.98
CN¥43.55
49.5%
PixArt Imaging (TPEX:3227)
NT$219.50
NT$436.51
49.7%
Peijia Medical (SEHK:9996)
HK$6.43
HK$12.71
49.4%
Livero (TSE:9245)
¥1719.00
¥3376.98
49.1%
Good Will Instrument (TWSE:2423)
NT$43.90
NT$87.32
49.7%
Food & Life Companies (TSE:3563)
¥6579.00
¥12942.09
49.2%
Dive (TSE:151A)
¥917.00
¥1832.47
50%
cottaLTD (TSE:3359)
¥442.00
¥866.08
49%
Click here to see the full list of 292 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.
Here we highlight a subset of our preferred stocks from the screener.
Overview: S&D Co., Ltd, with a market cap of ₩397.75 billion, develops and sells health functional food in South Korea.
Operations: Revenue Segments (in millions of ₩):
Estimated Discount To Fair Value: 23.1%
S&D Co., Ltd is trading at ₩137,500, which is 23.1% below its estimated fair value of ₩178,875.67, indicating it may be undervalued based on cash flows. The company's earnings are forecast to grow significantly at 23.4% annually, outpacing the Korean market's average growth rate of 21%. Revenue growth is also expected to exceed market averages at 20.9% per year. However, recent share price volatility could pose risks for investors seeking stability.
The analysis detailed in our S&D growth report hints at robust future financial performance.
Click to explore a detailed breakdown of our findings in S&D's balance sheet health report.
Overview: DPC Dash Ltd, along with its subsidiaries, runs a chain of fast-food restaurants in the People's Republic of China and has a market cap of HK$12.92 billion.
Operations: The company generates revenue primarily from its chain of fast-food restaurants in the People's Republic of China, totaling CN¥4.31 billion.
Estimated Discount To Fair Value: 17.9%
DPC Dash Ltd, trading at HK$98.7, is priced 17.9% below its fair value estimate of HK$120.2, reflecting potential undervaluation based on cash flows. The company recently turned profitable with net income of CNY 55.2 million and expects earnings to grow significantly at 51.3% annually, surpassing the Hong Kong market's growth rate of 10.6%. However, significant insider selling over the past quarter could be a concern for investors evaluating stability and confidence in future performance.
Our growth report here indicates DPC Dash may be poised for an improving outlook.
Click here and access our complete balance sheet health report to understand the dynamics of DPC Dash.
Overview: Peijia Medical Limited, with a market cap of HK$4.28 billion, focuses on the research, development, manufacturing, and sales of transcatheter valve therapeutic and neurointerventional procedural medical devices in the People's Republic of China.
Operations: Peijia Medical generates revenue from its Neurointerventional Business, which accounts for CN¥355.55 million, and its Transcatheter Valve Therapeutic Business, contributing CN¥259.94 million.
Estimated Discount To Fair Value: 49.4%
Peijia Medical, trading at HK$6.43, is significantly undervalued based on cash flows with a fair value estimate of HK$12.71. Despite reporting a net loss of CNY 226.58 million in 2024, the company is expected to become profitable within three years and outpace market growth with projected revenue increases of 27.9% annually. Recent advancements include regulatory acceptance for innovative medical devices and successful clinical trials, potentially enhancing future revenue streams and investor confidence.
Upon reviewing our latest growth report, Peijia Medical's projected financial performance appears quite optimistic.
Take a closer look at Peijia Medical's balance sheet health here in our report.
Delve into our full catalog of 292 Undervalued Asian Stocks Based On Cash Flows here.
Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include KOSDAQ:A260970 SEHK:1405 and SEHK:9996.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Clover Initiates Phase I Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates
-- Potential First-in-Class Respiratory Combination Vaccine Candidates SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) Enter the Clinical Trial Stage -- SHANGHAI, June 17, 2025 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced that enrollment of the first participants has been completed in a Phase I clinical trial evaluating SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3) respiratory combination vaccine candidates based on prefusion-stabilized F (PreF)-Trimer subunit vaccine antigens utilizing Clover's Trimer-Tag vaccine technology platform. "We are pleased to announce the Phase I clinical trial initiation of our potential first-in-class combination vaccine candidates SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3), further demonstrating the differentiated value of our validated Trimer-Tag platform," said Joshua Liang, Chief Executive Officer & Board Director of Clover. "While currently approved protein-based RSV vaccines are safe & effective, critical gaps persist globally, including the inability to prevent significant respiratory disease burden caused by other viruses related to RSV such as human metapneumovirus (hMPV) and parainfluenza virus type 3 (PIV3). Thus, we look forward to the clinical trial results for our respiratory combination vaccine candidates in order to maximize our impact on public health globally." In October 2024, Clover announced Phase I results in 70 older adults (60-85 years) for Clover's non-adjuvanted RSV PreF vaccine candidate (SCB-1019) compared head-to-head to GSK's AS01E-adjuvanted RSV vaccine (AREXVY), and results indicated a potential best-in-class combined immunogenicity & tolerability profile of SCB-1019. These results supported the further development and evaluation of SCB-1019 in combination with the PreF-Trimer antigens for hMPV and PIV3, which are also utilizing the Trimer-Tag platform. The ongoing Phase I trial for Clover's combination vaccine candidates is enrolling up to 192 older adults (60-85 years), and the participants will be randomized to receive either SCB-1022 (RSV+hMPV), SCB-1033 (RSV+hMPV+PIV3) or SCB-1019 (RSV) comparator. The study will assess safety, reactogenicity and immunogenicity. About Clover Clover Biopharmaceuticals is a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world. With integrated research and development, manufacturing and commercial capabilities as well as strong partnerships with organizations globally, Clover has a diverse pipeline of candidates that have the potential to meaningfully reduce the burden of vaccine-preventable diseases—and to make more diseases preventable. Clover Forward-looking Statements This press release contains certain forward-looking statements and information relating to us and our subsidiaries that are based on the beliefs of our management as well as assumptions made by and information currently available to our management. When used, the words "aim," "anticipate," "believe," "could," "estimate," "expect," "going forward," "intend," "may," "might," "ought to," "plan," "potential," "predict," "project," "seek," "should," "will," "would" and the negative of these words and other similar expressions, as they relate to us or our management, are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. We give no assurance that these expectations and assumptions will prove to have been correct. Because forward-looking statements relate to the future, they are participant to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. We caution you therefore against placing undue reliance on any of these forward-looking statements. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time. View original content: SOURCE Clover Biopharma Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
Undiscovered Gems in Asia to Explore This June 2025
As geopolitical tensions in the Middle East and trade-related concerns weigh on global markets, Asian stocks present a unique landscape of opportunities. With small-cap indices experiencing volatility, discerning investors may find potential in lesser-known companies that demonstrate resilience and innovation amidst changing economic conditions. Name Debt To Equity Revenue Growth Earnings Growth Health Rating Toho 72.03% 6.01% 64.19% ★★★★★★ Yashima Denki 2.40% 0.14% 21.00% ★★★★★★ FALCO HOLDINGS 4.93% -0.16% 1.44% ★★★★★★ Hefei Gocom Information TechnologyLtd NA 9.11% -12.23% ★★★★★★ Center International GroupLtd 18.20% 0.69% -31.63% ★★★★★★ ISE Chemicals 1.40% 15.34% 32.61% ★★★★★★ Shanghai SK Automation TechnologyLtd 37.27% 33.22% 12.18% ★★★★★☆ Guangdong Transtek Medical Electronics 18.14% -7.58% -3.26% ★★★★★☆ Daoming Optics&ChemicalLtd 33.83% 1.38% 5.82% ★★★★★☆ ITCENGLOBAL 66.11% 16.65% 1.99% ★★★★★☆ Click here to see the full list of 2614 stocks from our Asian Undiscovered Gems With Strong Fundamentals screener. Underneath we present a selection of stocks filtered out by our screen. Simply Wall St Value Rating: ★★★★★★ Overview: Snt Dynamics Ltd. engages in the manufacturing and sale of precision machinery, with a market capitalization of ₩1.25 trillion. Operations: Snt Dynamics Ltd. generates revenue primarily from its Machinery Business and Transportation Equipment Business, with the latter contributing significantly more at ₩672.52 billion compared to the former's ₩2.88 billion. Snt Dynamics Ltd. stands out in the aerospace and defense sector with a robust 96% earnings growth over the past year, surpassing industry averages. Despite its small size, this debt-free company boasts a favorable price-to-earnings ratio of 12.4x, slightly undercutting the KR market's 12.6x benchmark. Recent financials reveal net income at KRW 17,769 million for Q1 2025, up from KRW 12,880 million last year. The firm announced a private placement to issue bonds worth KRW 110 billion which are fully exchangeable into shares starting July 2025; such strategic moves may bolster future growth prospects significantly. Get an in-depth perspective on Snt DynamicsLtd's performance by reading our health report here. Evaluate Snt DynamicsLtd's historical performance by accessing our past performance report. Simply Wall St Value Rating: ★★★★★☆ Overview: Daou Technology Inc., along with its subsidiaries, offers IT and finance services and has a market capitalization of approximately ₩1.42 trillion. Operations: Daou Technology Inc. generates revenue primarily from its finance segment, with significant contributions from the Finance - Wholesale General Manager (₩8.22 billion) and Finance - Retail General Manager (₩2.52 billion) divisions. The non-financial segment includes System Construction, which adds ₩452.49 million to the revenue stream. Daou Technology, a noteworthy player in the tech sector, has shown impressive financial strides. With earnings growth of 76.1% over the past year, it outpaced its industry peers significantly. The company reported sales of KRW 21.28 billion for Q1 2025, up from KRW 12.50 billion last year, though net income slightly dipped to KRW 102.11 million from KRW 103.12 million previously. Despite not being free cash flow positive, Daou's interest payments are well-covered by EBIT at a robust rate of 97 times coverage and its debt-to-equity ratio improved from over five years to stand at a healthier level today. Dive into the specifics of Daou Technology here with our thorough health report. Assess Daou Technology's past performance with our detailed historical performance reports. Simply Wall St Value Rating: ★★★★☆☆ Overview: Gallant Micro. Machining Co., Ltd. specializes in the production and sale of machinery, equipment, precision molds, and various components across Taiwan, China, and international markets with a market cap of NT$16.65 billion. Operations: Gallant Micro. Machining Co., Ltd. generates revenue primarily from its machinery and equipment segment, with NT$1.81 billion attributed to this area, supplemented by contributions from KMC Corporation at NT$755.95 million. Gallant Micro. Machining, a small player in the semiconductor space, has shown impressive earnings growth of 40.9% over the past year, outpacing the industry's 10.8%. Despite this growth, their recent Q1 2025 results reported a drop in sales to TWD 430.22 million from TWD 695.32 million and net income to TWD 45.84 million from TWD 139.36 million year-over-year, reflecting challenges amid volatility in share prices over three months. The debt-to-equity ratio has increased significantly from 44% to 91%, though with a satisfactory net debt level at just over 13%, interest coverage remains solid and non-cash earnings are high. Click here and access our complete health analysis report to understand the dynamics of Gallant Micro. Machining. Examine Gallant Micro. Machining's past performance report to understand how it has performed in the past. Investigate our full lineup of 2614 Asian Undiscovered Gems With Strong Fundamentals right here. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSE:A003570 KOSE:A023590 and TPEX:6640. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
an hour ago
- Yahoo
Chinese Automakers Gain Ground in Global EV Race as Other World Leaders Risk Falling Behind
New ICCT report reveals China's growing advantage in EV sales as BYD edges past Tesla in global BEV sales for the first time WASHINGTON, June 17, 2025 /PRNewswire/ -- The International Council on Clean Transportation (ICCT) today released its third annual Global Automaker Rating, showing that China-based automakers are building significant leads in the zero-emission vehicle (ZEV) market as the country now accounts for over 11 million electric vehicles sold annually – more than half of global EV sales. Chinese manufacturers occupied the top 5 positions in ZEV class coverage and 5 of 6 top positions for EV sales share, with companies like Geely and SAIC already reaching 50% EV sales share, meeting their 2025 targets a year ahead of schedule. Among the report's other key findings, BYD exceeded Tesla in global battery electric vehicle (BEV) sales for the first time in 2024, with a 25% increase in BEV sales and 47% increase in combined BEV and plug-in hybrid electric vehicle sales compared to 2023. Both companies remain in the "Leaders" category. "Our assessment revealed widespread improvement in BEV technology performance across the industry," said Zifei Yang, ICCT's Global Passenger Vehicle Lead and principal author. "The vast majority of automakers demonstrated enhancements in energy consumption, charging speed, and driving range. GM and Honda made significant advancements by introducing high-performance models to their previously limited offerings." In a significant milestone, India-based Tata Motors became the first major automaker to transition from the "laggard" group to the "transitioner" group by introducing new EV models and ramping up battery recycling efforts. The report also highlights the increasing importance of manufacturing emissions through a newly introduced green steel metric, with automakers like Mercedes-Benz, BMW, and Volkswagen scoring well on sustainable procurement efforts. "Investors increasingly recognize that automakers embracing the EV transition aren't just preparing for regulatory compliance—they're positioning themselves for long-term market leadership," said Michael Kodransky, Senior Director at Ceres. "As China-based automakers expand globally, other leading global manufacturers face urgent pressure to accelerate their own transitions," said Drew Kodjak, ICCT President and CEO. "For the wider global auto industry, this is no longer just about meeting future goals – it's about remaining competitive today in a market that's charging up." See full report View original content to download multimedia: SOURCE The International Council on Clean Transportation (ICCT) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
